Takeda Pharmaceutical Company Limited (NYSE:TAK) was in 28 hedge funds’ portfolios at the end of September. Is Takeda Pharmaceutical Company Limited (TAK) A Good Stock To Buy? The sector with the best average Zacks Rank would be considered the top sector (1 out of 16), which would place it in the top 1% of Zacks Ranked Sectors. The company's largest segment  is gastrointestinal medicines, at 21% of sales in the first three quarters of fiscal 2019, and is delivering healthy sales growth, up 10%. Takeda Stock … Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. In this case, it's the cash flow growth that's being looked at. Note; companies will typically sell for more than their book value in much the same way that a company will sell at a multiple of its earnings. It is the most commonly used metric for determining a company's value relative to its earnings. This time period essentially shows you how the consensus estimate has changed from the time of their last earnings report. Put those segments together, along with a large part of the company's business (21% of sales) that the company says is outside of its focus areas and is shrinking at a double-digit rate, and the growth picture at the moment looks anemic. Of course, different industries will have different growth rates that are considered good. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank. The 1 Week Price Change displays the percentage price change over the last 5 trading days using the most recently completed close to the close from 5 days before. A P/B of 0.5 means its selling at half its book value. The 52 week price change is a good reference point. The EV/EBITDA ratio is a valuation multiple and is often used in addition, or as an alternative, to the P/E ratio. The change is made all the more important the closer proximity it is to the stock's earnings date since it is generally believed that the most recent estimates are the most accurate since it's using the most up-to-date information leading up to the report. That means these items are added back into the net income to produce this earnings number. It measures a company's ability to pay short-term obligations. Should I buy Takeda Pharmaceutical Co. (TAK)? The X Industry (aka Expanded Industry) is a subset of the M (Medium Sized) Industry, which is a subset of the larger Sector category, which is used to classify all of the stocks in the Zacks Universe. This includes personalizing content and advertising. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. A 'good' number would usually fall within the range of 1.5 to 3. Growth traders and investors will tend to look for growth rates of 20% or higher. The 4 week price change is a good reference point for the individual stock and how it's performed in relation to its peers. It plans to take out $2 billion in costs, divest $10 billion in non-core assets that are pulling down its growth rate, and pay off much of the debt it took on to buy Shire. While the hover-quote on Zacks.com, as well as the various tables, displays the delayed intraday quote and price change, this display shows the daily change as of the most recently completed trading day. This is also referred to as the cash yield. Above 1 means it assets are greater than its liabilities. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers. Looking to buy Takeda Pharmaceutical stock? Get the stock price and latest news for TAK and start trading today with zero commissions. ET by Jaimy Lee Karyopharm's stock jumps on trial results for multiple myeloma combo candidate Investors like this metric as it shows how a company finances its operations, i.e., what percentage is financed thru shareholder equity or debt. The Projected Sales Growth (F1/F0) looks at the estimated growth rate for the current year. Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Its Value Score of A indicates it would be a good pick for value investors. Like most ratios, this number will vary from industry to industry. These returns cover a period from January 1, 1988 through January 4, 2021. There probably aren't too many companies listed on the New York Stock Exchange with an operating history going back over 230 years that are virtually unknown to U.S. investors. Entyvio sales are growing at 35%, and beat AbbVie's mega-blockbuster Humira in a head-to-head trial in UC last year. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. A change in margin can reflect either a change in business conditions, or a company's cost controls, or both. Delayed quotes by Sungard. Using this item along with the 'Current Cash Flow Growth Rate' (in the Growth category above), and the 'Price to Cash Flow ratio' (several items above in this same Value category), will give you a well-rounded indication of the amount of cash they are generating, the rate of their cash flow growth, and the stock price relative to its cash flow. Value Style - Learn more about the Value Style. A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its annual earnings. Ideally, an investor would like to see a positive EPS change percentage in all periods, i.e., 1 week, 4 weeks, and 12 weeks. Takhzyro for hereditary angioedema is growing well, but not enough to overcome losses by older drugs for the same condition. Our testing substantiates this with the optimum range for price performance between 0-20. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. A higher number is better than a lower number. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Within the Finance Sector, it would fall into the M Industry of Banks & Thrifts. Conventional wisdom also has it that if the yield on the stock market (S&P 500 for example) is lower that the yield on the 10 Yr., then stocks would be considered overvalued. Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). A huge acquisition could get this overlooked giant on investors' radar. If a company's net margin is 15%, for example, that means its net income (or profit) is 15 cents for every $1 of sales the company makes. Learn more about Zacks Equity Research reports. ROE values, like other values, can vary significantly from one industry to another. It was updated on Sept. 10, 2020, to reflect the latest available information. Takeda Pharmaceutical Co Ltd (TAK) stock is trading at $18.39 as of 10:53 AM on Wednesday, Dec 2, a rise of $0.42, or 2.34% from the previous closing price of $17.97. A higher number is better than a lower one as it shows how effective a company is at generating revenue from its assets. The stock has traded between $17.95 and $18.16 so far today. A P/S ratio of 2 means you're paying $2 for every $1 of sales the company makes. Zacks Rank Education -- Learn more about the Zacks Rank A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). This list of both classic and unconventional valuation items helps separate which stocks are overvalued, rightly lowly valued, and temporarily undervalued which are poised to move higher. A ratio of 2 means its assets are twice that of its liabilities. The analyzed items go beyond simple trend analysis. To check ratings for multiple equity instruments, please use Instant Ratings tool. We use cookies to understand how you use our site and to improve your experience. Growth Style - Learn more about the Growth Style. Edit #1 1/23/21, 22:34: Yes this stock is flat/declining as fuck. In the meantime, sales growth is flat, and any profit growth will be coming from cost cutting. The stock should be watched closely. The Historical Cash Flow Growth is the longer-term (3-5 year annualized) growth rate of the cash flow change. The plan has been for the Shire integration to complete by March 2024, but the company surprised the market this month when it said in its third quarter report that it expected to make a small operating profit for the full year after earlier forecasting a $1 billion operating loss. Strong Buy: 24.41%: 2: Buy: 17.88%: 3: Hold: 9.48%: 4: Sell: 5.03%: 5: Strong Sell: 1.87%: S&P: 500: 10.70% The Cash/Price ratio is calculated as cash and marketable securities per share divided by the stock price. The Hertz Global Holdings Inc stock price gained 34.38% on the last trading day (Friday, 5th Mar 2021), rising from $0.66 to $0.89.During the day the stock fluctuated 82.83% from a day low at $0.52 to a day high of $0.95. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Ever wondered how to buy shares in Takeda Pharmaceutical Company Limited? TAK has seen an increase in enthusiasm from smart money lately. Momentum Style - Learn more about the Momentum Style. If the P/S ratio is 1, that means you're paying $1 for every $1 of sales the company makes. The Sales to Assets ratio (or Sales to Total Assets or S/TA for short) shows how much sales are generated from a company's assets. A higher number means the company has more debt to equity, whereas a lower number means it has less debt to equity. Competition is hurting its drugs for blood diseases, and a recall of Natpara for hypoparathyroidism has the company assuming zero U.S. sales for that drug in 2020. This measure is expressed as a percentage. Jim bought his first stocks in 1967 with paper route money and has been invested in equities ever since. This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. While they are good value, they show below average growth, and are riskily financed. $25 $50 $100 $500 $1,000 $2,000 A Different Amount. +0.15 (0.82%) Takeda Pharmaceutical Co. (TAK) Quote Overview, Takeda Pharmaceutical Co. (TAK) Style Scores, Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Beat on Galafold, Denali's (DNLI) Q4 Earnings & Revenues Beat on Biogen Deal. Enterprise Value (EV) is Market Capitalization + Debt - Cash. But they all have their place in the Growth style. You may be able to buy a fractional share of Takeda Pharmaceutical Company, depending on your broker. It's calculated as earnings divided by price. Plus, Takeda stock is a recently added DIY top pick idea for subscribers. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. For one, part of trading is being able to get in and out of a stock easily. @themotleyfool #stocks $TAK $SGEN $ABBV, Novavax Partners With Takeda to Sell Its Coronavirus Vaccine in Japan, Convalescent Plasma Found to Reduce COVID-19 Death Rate in New Study, 3 Coronavirus Stocks With the Highest Dividend Yields. Takeda Pharmaceutical currently has 1 buy rating from Wall Street analysts. The 1 week price change reflects the collective buying and selling sentiment over the short-term. Additionally, take a look at TAKEDA PHARMACEUTICAL Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. Note: there are many factors that can influence the longer-term number, not the least of which is the overall state of the economy (recession will reduce this number for example, while a recovery will inflate it), which can skew comparisons when looking out over shorter time frames. More . Historical EPS Growth Rate looks at the average annual (trailing 12 months) EPS growth rate over the last 3-5 years of actual earnings. The stock hasn’t participated in the great growth boom like other pharmaceutical stocks, but this company is in it for the long haul. Returns as of 03/10/2021. How good is it? A D/E ratio of 1 means its debt is equivalent to its common equity. Zacks' proprietary data indicates that Takeda Pharmaceutical Co. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the TAK shares relative to the market in the next few months. Check in on your investment. Apr. Takeda has partnerships with a number of U.S. pharmaceutical companies, and made headlines in 2018 when it announced plans for a massive acquisition of Shire that was completed about a year ago. In general, the lower the ratio is the better. On the downside, the stock finds support just below today's level from accumulated volume at $41.93 and $40.79. Zacks Rank Education - Learn about the Zacks Rank, Zacks Rank Home - Zacks Rank resources in one place, Zacks Premium - The only way to fully access the Zacks Rank. NASDAQ data is at least 15 minutes delayed. The (Q1) EPS Estimate Monthly Change calculates the percentage change in the consensus earnings estimate for the current quarter (Q1) over the last 4 weeks. The 20 day average establishes this baseline. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score. A successful execution of its plan would help Takeda invest in research and development in its focus areas, where it already has a significant number of drug candidates in the clinic. This is a medium-term price change metric (like the 4 week price change). If a company's expenses are growing faster than their sales, this will reduce their margins. Others will look for a pullback on the week as a good entry point, assuming the longer-term price changes (4 week, 12 weeks, etc.) The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. A partnership with cancer specialist Seattle Genetics to co-develop and commercialize that company's lead drug, Adcetris, should be a potent growth driver for years. It is used to help gauge a company's financial health. Visit www.zacksdata.com to get our data and content for your mobile app or website. If you are looking for stocks with good return, Takeda Pharmaceutical Company Limited stock can be a bad, high-risk 1-year investment option. Who Can Donate Plasma for COVID-19 Patients?